Pseudolymphoma is not cancer. It is a benign buildup of inflammatory cells that looks remarkably like lymphoma, both to the naked eye and under a microscope, but it lacks the uncontrolled cell growth that defines a true malignancy. That said, it does carry a small risk of progression that makes proper diagnosis and follow-up important.
What Pseudolymphoma Actually Is
Pseudolymphoma, also called cutaneous lymphoid hyperplasia, is an inflammatory reaction rather than a cancerous process. Something triggers your immune system to send a dense collection of white blood cells to a specific area, usually the skin. The result is a nodule or plaque that can fool even experienced pathologists into thinking it’s lymphoma. The key difference: the immune cells in pseudolymphoma are a diverse, mixed population (polyclonal), while lymphoma cells are copies of a single abnormal cell (monoclonal).
It typically appears as a skin-colored or reddish nodule on the face or chest, though it can show up elsewhere. Lesions are usually small, around 1 to 2 centimeters, and may cause mild itching or tenderness. Some people develop a single spot, while others get multiple or widespread lesions.
Known Triggers
Many cases are idiopathic, meaning no clear cause is ever identified. When a trigger is found, it usually falls into one of several categories:
- Medications: Anticonvulsants are the most common drug culprits, particularly phenytoin and carbamazepine. Other reported triggers include certain immunosuppressants, antibiotics like vancomycin, antidepressants like fluoxetine, blood pressure medications, and biologic drugs used for autoimmune conditions.
- Infections: The bacteria that causes Lyme disease (Borrelia burgdorferi), varicella zoster virus, and HIV have all been linked to pseudolymphoma.
- Physical stimuli: Insect bites, tattoos, minor trauma, vaccinations, jewelry contact, and sun sensitivity can all provoke the reaction.
Identifying the trigger matters because removing it is often the most effective treatment. Drug-induced cases, for example, frequently resolve once the medication is stopped.
The Small Risk of Progression
This is the part that makes pseudolymphoma worth taking seriously. While the condition itself is benign, a small percentage of cases do eventually progress to actual lymphoma. In one study that followed 44 patients with pseudolymphoma for 24 months, 2 cases (about 4%) progressed to cutaneous B-cell lymphoma. One of those cases had shown signs of monoclonality on testing, but the other had not, which means even apparently “low-risk” cases can occasionally transform.
A 4% progression rate over two years is low, but it’s not zero. This is why doctors recommend ongoing monitoring even after successful treatment. Pseudolymphoma is best understood as a condition that is overwhelmingly benign but requires periodic check-ins to catch the rare case that changes character.
Why Diagnosis Can Be Difficult
The biggest practical danger of pseudolymphoma isn’t the condition itself. It’s the risk of misdiagnosis. Distinguishing it from true lymphoma is considered one of the most challenging tasks in skin pathology. The two conditions can look nearly identical on a standard biopsy, and the list of conditions that mimic cutaneous lymphoma is long and growing.
To tell them apart, pathologists rely on specialized staining techniques called immunohistochemistry. By testing the immune cells for specific surface markers, they can determine whether the cell population is polyclonal (diverse, pointing to pseudolymphoma) or monoclonal (uniform, pointing to lymphoma). A biopsy alone isn’t always enough. If there’s any doubt, additional testing or a second opinion from a specialist is reasonable.
Misdiagnosis can go in both directions. A pseudolymphoma mistaken for lymphoma could lead to unnecessarily aggressive treatment. A lymphoma mistaken for pseudolymphoma could delay critical care. Getting an accurate diagnosis is the single most important step.
Treatment and What to Expect
Some pseudolymphoma lesions resolve on their own, and a few have even disappeared after the biopsy procedure itself. For persistent lesions, the range of options is broad: topical or injected corticosteroids, surgical removal, cryotherapy (freezing), laser treatment, and light-based therapies. The choice depends on the size, location, and number of lesions.
For cases without symptoms, a “watch and wait” approach may be appropriate after careful evaluation. Lesions can persist anywhere from a few weeks to several years, so patience is sometimes part of the plan.
Recurrence is a realistic possibility. Even after lesions clear completely, new ones can appear months or years later. This is particularly true when the underlying trigger hasn’t been identified or removed. Long-term follow-up with periodic skin checks helps catch both recurrences and the rare progression to lymphoma early, when either is most manageable.
Bottom Line on Risk
Pseudolymphoma is not dangerous in the way that cancer is dangerous. It won’t spread through your body or damage organs. The lesions themselves are cosmetically bothersome more than medically threatening. The two real concerns are getting an accurate diagnosis in the first place and maintaining follow-up to catch the roughly 1-in-25 chance of progression over time. With proper identification and monitoring, the vast majority of people with pseudolymphoma have an excellent long-term outcome.